Final Analysis of a Trial of M72/AS01

Abstract

BACKGROUND: Results of an earlier analysis of a trial of the M72/AS01 METHODS: From August 2014 through November 2015, we enrolled adults 18 to 50 years of age with RESULTS: A total of 3575 participants underwent randomization, of whom 3573 received at least one dose of M72/AS01 CONCLUSIONS: Among adults infected with

Description

Keywords

Citation

Collections

Endorsement

Review

Supplemented By

Referenced By